Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

ISSUANCE OF EQUITY INTERESTS (Details)

ISSUANCE OF EQUITY INTERESTS (Details)												9 Months Ended
ISSUANCE OF EQUITY INTERESTS (Details)	Apr. 15, 2026 USD ($) $ / shares shares	Aug. 04, 2025	Jun. 20, 2025 USD ($) $ / shares shares	Jun. 17, 2025 USD ($) $ / shares shares	May 08, 2025 USD ($) $ / shares shares	Mar. 06, 2025 USD ($) $ / shares shares	Jan. 06, 2025 USD ($) $ / shares shares	Nov. 15, 2023 USD ($)	May 18, 2023 USD ($) shares	Jul. 27, 2022 USD ($) shares	Jun. 29, 2021 USD ($) $ / shares shares	Sep. 30, 2026 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Dec. 31, 2025 $ / shares
Equity
Reverse stock split conversion ratio		0.05
Shares issued (in shares)	816,068
Share sales price (in dollars per share) \| $ / shares	$ 3.03										$ 120
Proceeds from stock issue \| $	$ 2,500,000								$ 4,000,000	$ 4,200,000	$ 17,300,000
Warrants issued (in shares)	1,650,170											1,659,187
Warrant exercise price (in dollars per share) \| $ / shares	$ 2.78
Common stock par value (in dollars per share) \| $ / shares	$ 0.001											$ 0.001		$ 0.001
Pre-funded warrants
Equity
Warrants issued (in shares)	9,017								36,574	6,538
Warrant exercise price (in dollars per share) \| $ / shares	$ 3.029
Series A warrants
Equity
Warrants issued (in shares)										64,499
Series B warrants
Equity
Warrants issued (in shares)										64,499
Series C warrants
Equity
Warrants issued (in shares)									66,667
Series D warrants
Equity
Warrants issued (in shares)									66,667
Common Stock
Equity
Shares issued (in shares)									30,093	57,961	143,750
Underwriter option \| Series E warrants
Equity
Warrants issued (in shares)							7,389
Warrant exercise price (in dollars per share) \| $ / shares							$ 25.38
Fair value of Warrants \| $							$ 85,419
Underwriter option \| Series F warrants
Equity
Warrants issued (in shares)						8,235
Warrant exercise price (in dollars per share) \| $ / shares						$ 10
Fair value of Warrants \| $						$ 56,163
Underwriter option \| Measurement Input, Expected Term \| Series E warrants
Equity
Warrants term							5 years
Underwriter option \| Measurement Input, Expected Term \| Series F warrants
Equity
Warrants term						5 years
Underwriter option \| Measurement Input, Risk Free Rate \| Series E warrants
Equity
Measurement Input, Warrants							4.46
Underwriter option \| Measurement Input, Risk Free Rate \| Series F warrants
Equity
Measurement Input, Warrants						3.98
Underwriter option \| Measurement Input, Share Price \| Series E warrants
Equity
Measurement Input, Warrants							16.2
Underwriter option \| Measurement Input, Share Price \| Series F warrants
Equity
Measurement Input, Warrants						9
Underwriter option \| Measurement Input, Volatility \| Series E warrants
Equity
Measurement Input, Warrants							102
Underwriter option \| Measurement Input, Volatility \| Series F warrants
Equity
Measurement Input, Warrants						102
January 2025 Registered Direct Offering
Equity
Share sales price (in dollars per share) \| $ / shares							$ 20.3
Proceeds from stock issue \| $							$ 2,500,000
Net proceeds stock issuance \| $							$ 2,100,000
January 2025 Registered Direct Offering \| Series E warrants
Equity
Warrants issued (in shares)							123,153
Warrant exercise price (in dollars per share) \| $ / shares							$ 18
Warrants term							5 years
January 2025 Registered Direct Offering \| Affiliate Investors \| Series E warrants
Equity
Warrants issued (in shares)							8,374
January 2025 Registered Direct Offering \| Investor \| Series E warrants
Equity
Warrants issued (in shares)							114,779
January 2025 Registered Direct Offering \| Common Stock
Equity
Shares issued (in shares)							123,153
January 2025 Registered Direct Offering \| Common Stock \| Affiliate Investors
Equity
Shares issued (in shares)							8,374
January 2025 Registered Direct Offering \| Common Stock \| Investor
Equity
Shares issued (in shares)							114,779
March 2025 Registered Direct Offering
Equity
Share sales price (in dollars per share) \| $ / shares						$ 8
Proceeds from stock issue \| $						$ 1,100,000
Net proceeds stock issuance \| $						$ 900,000
March 2025 Registered Direct Offering \| Pre-funded warrants
Equity
Warrants issued (in shares)						29,750
Warrant exercise price (in dollars per share) \| $ / shares						$ 7.998
March 2025 Registered Direct Offering \| Series F warrants
Equity
Warrants issued (in shares)						411,750
Warrant exercise price (in dollars per share) \| $ / shares						$ 8
Warrants term						24 months
March 2025 Registered Direct Offering \| Common Stock
Equity
Shares issued (in shares)						107,500
At the Market Offering
Equity
Maximum value of offering \| $								$ 17,000,000
Equity Line of Credit Purchase Agreement
Equity
Shares issued (in shares)					44,963							2,598,154	393,532
Share sales price (in dollars per share) \| $ / shares					$ 2.12							$ 2.12	$ 6.18
Proceeds from stock issue \| $												$ 5,512,971	$ 2,433,823
Net proceeds stock issuance \| $												$ 5,432,314	$ 2,334,945
Maximum value of offering \| $					$ 12,000,000
Non-cash equity issuance costs \| $					360,000
Equity Line of Credit Purchase Agreement \| Common Stock
Equity
Maximum value of offering \| $					$ 12,000,000
Common stock par value (in dollars per share) \| $ / shares					$ 0.001
Warrant Inducement Agreement
Equity
Proceeds from stock issue \| $				$ 2,700,000
Net proceeds stock issuance \| $				$ 2,500,000
Warrants issued (in shares)				222,272
Warrant exercise price (in dollars per share) \| $ / shares				$ 12
Warrant Inducement Agreement \| Series A warrants
Equity
Warrants issued (in shares)				61,538
Warrant exercise price (in dollars per share) \| $ / shares				$ 65
Warrant Inducement Agreement \| Series B warrants
Equity
Warrants issued (in shares)				27,400
Warrant exercise price (in dollars per share) \| $ / shares				$ 65
Warrant Inducement Agreement \| Series C warrants
Equity
Warrants issued (in shares)				66,667
Warrant exercise price (in dollars per share) \| $ / shares				$ 65.2
Warrant Inducement Agreement \| Series D warrants
Equity
Warrants issued (in shares)				66,667
Warrant exercise price (in dollars per share) \| $ / shares				$ 65.2
Warrant Inducement Agreement \| Series G Warrants
Equity
Warrant exercise price (in dollars per share) \| $ / shares				$ 8.5
Non-cash equity issuance costs \| $			$ 4,527,245
Warrant Inducement Agreement \| Series G-1 Warrants
Equity
Warrants issued (in shares)				311,180
Warrants term				5 years
Warrant Inducement Agreement \| Series G-2 Warrants
Equity
Warrants issued (in shares)				133,363
Warrants term				5 years
Warrant Inducement Agreement \| H.C. Wainwright & Co.
Equity
Percentage of private placement offerings warrant coverage			7.00%
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Underwriter's Warrants
Equity
Warrants issued (in shares)			13,336
Warrant exercise price (in dollars per share) \| $ / shares			$ 15
Fair value of Warrants \| $			$ 109,624
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Expected Term \| Underwriter's Warrants
Equity
Warrants term			5 years
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Risk Free Rate \| Underwriter's Warrants
Equity
Measurement Input, Warrants			3.96
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Share Price \| Underwriter's Warrants
Equity
Measurement Input, Warrants \| $ / shares			11
Warrant Inducement Agreement \| H.C. Wainwright & Co. \| Measurement Input, Volatility \| Underwriter's Warrants
Equity
Measurement Input, Warrants			105